NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer

NCT02429804 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped Accrual factor

Conditions

Hormone-Resistant Prostate Cancer
Metastatic Malignant Neoplasm in the Bone
Metastatic Prostate Carcinoma

Interventions

PROCEDURE: Contrast-enhanced Magnetic Resonance Imaging
DRUG: Fludeoxyglucose F-18
DRUG: Fluorine F 18 Sodium Fluoride
PROCEDURE: Magnetic Resonance Imaging
PROCEDURE: Positron Emission Tomography

Sponsor

Stanford University

Collaborators

[object Object]